Key Takeaways:
CHICAGO, IL – Cosmos Health Inc. (NASDAQ:COSM) reported record financial results for the full year 2025, with revenue hitting an all-time high of $65.3 million, a 20 percent increase from the previous year.
"These historic results reflect the successful execution of our strategy across all core segments," said CEO Greg Siokas, who increased his ownership by over 3.3 million shares. "Our strong momentum is continuing into 2026."
The healthcare group's performance was driven by significant growth in its contract manufacturing division, expanded wholesale distribution, and the global expansion of its proprietary brands like Sky Premium Life. Gross profit surged 83 percent to $7.9 million, with gross margin expanding by 418 basis points.
Shares of Cosmos Health reacted positively to the news, as the results signal strong operational efficiency and growth. The company also announced a new $300 million financing facility to launch a digital asset treasury strategy, a move that could attract new investors.
The company's contract manufacturing arm, Cana Laboratories, secured long-term agreements for over 12 million units. The Sky Premium Life brand portfolio was expanded by 60 SKUs, with purchase orders for over 300,000 units in new markets.
In a significant strategic development, Cosmos Health secured a $300 million financing facility to initiate a digital asset treasury. This move, along with advancements in its R&D pipeline including patented anticancer drugs and AI-driven patent filings, indicates a forward-looking growth strategy. The company's cash position increased tenfold to $3.5 million.
The strong full-year performance and the CEO's increased stake signal deep insider conviction in the company's trajectory. Investors will be watching for the execution of the digital asset strategy and continued expansion in the U.S. market throughout 2026.
This article is for informational purposes only and does not constitute investment advice.
